Xu N, Shen Y, Huang W, Nie J
Viruses. 2025; 17(2).
PMID: 40006926
PMC: 11860447.
DOI: 10.3390/v17020171.
Li Y, Lin Y, Yi Y, Zhu N, Cui X, Li X
Vaccines (Basel). 2025; 12(12.
PMID: 39772028
PMC: 11680300.
DOI: 10.3390/vaccines12121365.
Abavisani M, Ansari B, Ebadpour N, Sahebkar A
Clin Exp Vaccine Res. 2024; 13(4):271-300.
PMID: 39525670
PMC: 11543789.
DOI: 10.7774/cevr.2024.13.4.271.
Baldovin T, Leoni D, Geppini R, Miatton A, Amoruso I, Fonzo M
Vaccines (Basel). 2024; 12(10).
PMID: 39460338
PMC: 11512344.
DOI: 10.3390/vaccines12101172.
Alirezaylavasani A, Skeie L, Egner I, Chopra A, Dahl T, Prebensen C
NPJ Vaccines. 2024; 9(1):185.
PMID: 39384763
PMC: 11464709.
DOI: 10.1038/s41541-024-00972-3.
Evaluation of the Effect of mRNA and Inactivated SARS-CoV-2 Vaccines on the Levels of Cytokines IL-2, IFN-γ, and Anti-RBD Spike SARS-CoV-2 Antibodies in People Living with HIV (PLHIV).
Amanah A, Ariyanto I, Bela B, Primanagara R, Sudarmono P
Biomedicines. 2024; 12(9).
PMID: 39335628
PMC: 11429386.
DOI: 10.3390/biomedicines12092115.
Estimation of vaccine effectiveness against SARS-CoV-2-associated hospitalization using sentinel surveillance in South Africa.
Chiwandire N, Walaza S, von Gottberg A, Wolter N, du Plessis M, Moosa F
Int J Epidemiol. 2024; 53(5).
PMID: 39305220
PMC: 11415825.
DOI: 10.1093/ije/dyae116.
COVID-19 Breakthrough Infections Among People With HIV: A Statewide Cohort Analysis.
Yang X, Zhang J, Chen S, Liu Z, Poland G, Olatosi B
J Acquir Immune Defic Syndr. 2024; 97(2):107-116.
PMID: 39250644
PMC: 11386905.
DOI: 10.1097/QAI.0000000000003475.
COVID-19 vaccine updates for people under different conditions.
Huang Y, Wang W, Liu Y, Wang Z, Cao B
Sci China Life Sci. 2024; 67(11):2323-2343.
PMID: 39083202
DOI: 10.1007/s11427-024-2643-1.
Risk of breakthrough infection and hospitalisation after COVID-19 primary vaccination by HIV status in four Italian regions during 2021.
Mateo-Urdiales A, Fabiani M, Mayer F, Sacco C, Belleudi V, Da Cas R
BMC Public Health. 2024; 24(1):1569.
PMID: 38862939
PMC: 11165887.
DOI: 10.1186/s12889-024-19071-y.
T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.
Datwani S, Kalikawe R, Waterworth R, Mwimanzi F, Liang R, Sang Y
Viruses. 2024; 16(5).
PMID: 38793543
PMC: 11125792.
DOI: 10.3390/v16050661.
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
Riou C, Bhiman J, Ganga Y, Sawry S, Ayres F, Baguma R
PLOS Glob Public Health. 2024; 4(4):e0002703.
PMID: 38603677
PMC: 11008839.
DOI: 10.1371/journal.pgph.0002703.
Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopenia.
Rocco J, Boswell K, Laidlaw E, Epling B, Anderson M, Serebryannyy L
J Allergy Clin Immunol. 2024; 153(2):503-512.
PMID: 38344971
PMC: 10861932.
DOI: 10.1016/j.jaci.2023.10.012.
Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts.
Chittrakarn S, Siripaitoon P, Chusri S, Kanchanasuwan S, Charoenmak B, Hortiwakul T
Hum Vaccin Immunother. 2024; 20(1):2309734.
PMID: 38297904
PMC: 10841008.
DOI: 10.1080/21645515.2024.2309734.
Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine.
Vanetti C, Stracuzzi M, Crivellaro E, Ciciliano F, Garziano M, Fenizia C
Front Immunol. 2024; 14:1301766.
PMID: 38250079
PMC: 10797701.
DOI: 10.3389/fimmu.2023.1301766.
COVID-19 breakthrough infections among people living with and without HIV: A statewide cohort analysis.
Yang X, Zhang J, Liu Z, Chen S, Olatosi B, Poland G
Int J Infect Dis. 2023; 139:21-27.
PMID: 38013151
PMC: 10842358.
DOI: 10.1016/j.ijid.2023.11.029.
The immune response to SARS-CoV-2 in people with HIV.
Hoft M, Burgers W, Riou C
Cell Mol Immunol. 2023; 21(2):184-196.
PMID: 37821620
PMC: 10806256.
DOI: 10.1038/s41423-023-01087-w.
Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV.
Matveev V, Mihelic E, Benko E, Budylowski P, Grocott S, Lee T
iScience. 2023; 26(10):107915.
PMID: 37790281
PMC: 10542941.
DOI: 10.1016/j.isci.2023.107915.
Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus.
Tortellini E, Fosso Ngangue Y, Dominelli F, Guardiani M, Falvino C, Mengoni F
Viruses. 2023; 15(9).
PMID: 37766251
PMC: 10534440.
DOI: 10.3390/v15091844.
Response to BNT162b2 mRNA COVID-19 vaccine of ART-experienced people living with HIV: a prospective analysis from a single-center study in Rome, Italy.
Lombardi F, Belmonti S, Di Giambendetto S
Infez Med. 2023; 31(3):359-363.
PMID: 37701380
PMC: 10495060.
DOI: 10.53854/liim-3103-9.
